Kangji Medical Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Kangji Medical Holdings yıllık ortalama 21.5% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar growing at 14.7% annual. Gelirler growing yılda ortalama 15.5% oranında artmaktadır. Kangji Medical Holdings'in özkaynak karlılığı 21.1% ve net marjı 54.5%'dir.

Anahtar bilgiler

21.5%

Kazanç büyüme oranı

17.6%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	13.7%
Gelir büyüme oranı	15.5%
Özkaynak getirisi	21.1%
Net Marj	54.5%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Kangji Medical Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SZSC:9997 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	981	534	181	111
31 Mar 24	953	519	176	119
31 Dec 23	926	504	171	128
30 Sep 23	892	540	158	114
30 Jun 23	858	576	146	100
31 Mar 23	822	528	135	83
31 Dec 22	786	479	124	66
30 Sep 22	745	447	122	56
30 Jun 22	704	415	120	46
31 Mar 22	697	436	115	41
31 Dec 21	690	457	109	36
30 Sep 21	654	413	103	33
30 Jun 21	617	369	96	29
31 Mar 21	564	310	95	27
31 Dec 20	511	250	95	25
30 Sep 20	506	227	88	23
30 Jun 20	500	204	81	21
31 Mar 20	502	205	74	19
31 Dec 19	503	206	67	17
31 Dec 18	354	147	43	15
31 Dec 17	248	118	29	10

Kaliteli Kazançlar: 9997 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 9997 'nin mevcut net kar marjları (54.5%) geçen yılın (67.2%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 9997 şirketinin kazançları son 5 yılda yılda 21.5% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: 9997 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: 9997 geçtiğimiz yıl negatif kazanç büyümesine ( -7.3% ) sahipti ve bu da onu Medical Equipment sektör ortalamasıyla ( -4.3% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: 9997 'nin Özsermaye Getirisi ( 21.1% ) yüksek olarak değerlendiriliyor.

Kangji Medical Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in 1H 2023)

Kangji Medical Holdings Limited to Report First Half, 2024 Results on Aug 20, 2024

Full year 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.40 in FY 2022)

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.13 in 1H 2022)

Kangji Medical Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Recent updates

First half 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in 1H 2023)

Kangji Medical Holdings Limited to Report First Half, 2024 Results on Aug 20, 2024

Kangji Medical Holdings Limited Approves Special Dividend for the Year Ended 31 December 2023, Payable on 18 July 2024

Investor sentiment deteriorates as stock falls 26%

Upcoming dividend of CN¥1.40 per share

Full year 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.40 in FY 2022)

Kangji Medical Holdings Limited Proposes Special Dividend for the Year Ended December 31, 2023

Dividend of CN¥1.40 announced

Kangji Medical Holdings Limited, Annual General Meeting, May 27, 2024

Investor sentiment improves as stock rises 17%

Kangji Medical Holdings Limited Announces CFO Changes

Kangji Medical Holdings Limited Announces the Resignation of Frances Fang Chovanec as Executive Director, Member of Environmental, Social and Governance Committee with Effective from September 15, 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.13 in 1H 2022)

Kangji Medical Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Kangji Medical Holdings Limited Approves Payment of Final Dividend for the Year Ended December 31, 2022, Payment Date Is 10 July 2023

Full year 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.37 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 1H 2021)

Kangji Medical Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021, Payment date is 08 July 2022

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.17 per share

Kangji Medical Holdings Limited Announces Executive Changes

Full year 2021 earnings released: EPS: CN¥0.37 (vs CN¥0.26 in FY 2020)

Less than half of directors are independent

Kangji Medical Holdings Limited to Report Fiscal Year 2021 Results on Mar 22, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.16 (vs CN¥0.12 in 1H 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.20 in FY 2019)

Kangji Medical Holdings Limited Proposes Final Dividend for the Year Ended December 31, 2020

Investor sentiment improved over the past week

Full year 2020 earnings released

Kangji Medical Holdings Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

Investor sentiment deteriorated over the past week

New 90-day low: HK$10.88

Investor sentiment deteriorated over the past week

New 90-day low: HK$12.16

Investor sentiment deteriorated over the past week

New 90-day low: HK$13.86

Market pulls back on stock over the past week

Kangji Medical Holdings Limited Appoints Frances Fang Chovanec as Executive Director

First half earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin